Mumbai, February 5, 2025 – Medico Remedies Limited (BSE: 540937, NSE: MEDICO), a pharmaceutical formulations manufacturer, announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2024.
Key Financial Highlights (Standalone)
Quarterly Performance (Q3 FY2025 vs. Q3 FY2024)
Particulars
Q3 FY2025 (₹ in Lakhs)
Q3 FY2024 (₹ in Lakhs)
YoY Change (%)
Revenue from Operations
3,948.99
2,977.22
32.6%
Other Income
142.99
27.80
414.3%
Total Income
4,091.98
3,004.58
36.2%
Total Expenses
3,341.70
2,796.70
19.5%
Profit Before Tax (PBT)
79.14
66.76
18.5%
Profit After Tax (PAT)
261.97
144.53
81.3%
Basic & Diluted EPS (₹)
0.32
0.17
88.2%
Nine-Month Performance (9M FY2025 vs. 9M FY2024)
Particulars
9M FY2025 (₹ in Lakhs)
9M FY2024 (₹ in Lakhs)
YoY Change (%)
Revenue from Operations
10,359.79
7,544.88
37.4%
Other Income
239.34
151.42
58.0%
Total Income
10,599.13
7,696.30
37.7%
Total Expenses
10,022.52
7,988.75
25.4%
Profit Before Tax (PBT)
192.54
147.42
30.6%
Profit After Tax (PAT)
575.24
519.18
10.8%
Basic & Diluted EPS (₹)
0.69
0.63
9.5%
Segmental and Geographic Performance
Medico Remedies operates as a single segment under pharmaceutical formulations, per IND AS 108.
Region
Q3 FY2025 Revenue (₹ in Lakhs)
Q2 FY2025 Revenue (₹ in Lakhs)
Domestic Sales
71.47
244.40
Exports
3,842.90
3,655.85
Total Revenue
3,914.37
3,900.25
Exports remain the primary revenue driver, contributing significantly to overall sales growth.
Audit Review & Compliance
The financial results were reviewed by the Audit Committee and approved by the Board on February 5, 2025.
A Limited Review Report from V J Shah & Co. (Chartered Accountants) confirms no material misstatements in the financials.
The company has no subsidiaries, associates, or joint ventures as of December 31, 2024.
Management Commentary
Haresh Mehta, Chairman & Whole-Time Director, commented: "We continue to experience strong revenue growth, driven by our expanding export business. Our disciplined approach to cost management has further improved profitability. We remain optimistic about sustained performance in the coming quarters."
Strategic Outlook
Expansion in Export Markets: Strengthening global presence remains a key focus.
Operational Efficiency: Efforts continue to enhance cost efficiency and supply chain resilience.
Regulatory Compliance: The company remains committed to adhering to SEBI and accounting standards.
